Nagpur: The Food and Drugs Administration (FDA) has begun reviewing oxygen manufacturing status and filling plants in 12 private places to measure their readiness with the threat of omicrons towering large in the region.
It learned that examinations throughout the three-day state had been carried out by the FDA authority under the supervision of Commissioner of Parimal Singh.
The purpose behind this exercise is to ensure that plants are ready to cater with the supply needs of medical oxygen if demand suddenly rises due to the increasing patient.
In the last two waves, especially the second, acute lack of oxygen is felt throughout the state.
In Nagpur, oxygen must be brought from other countries on special Oxygen trains and the Indian Air Force (IAF) operator load.
During an emergency, some oxygen plants face technical barriers as well, which leads to supply disruption as a health care system collapsed under the demands of oxygen sleep.
FDA Assistant Commissioner PM Ballal said liquid medical oxygen manufacturers such as INOX Air Products in Butibori are being examined to ensure their current production capacity, fitness factory machines, storage capacity and parameters such as important for their functions and provide capabilities on peak needs.
“FDA officials will visit manufacturers, re-fillers and air units separating private ownership for inspection.
The report will be forwarded to the headquarters of Mumbai FDA to review the entire state, “Ballal said, adding that the commissioner with Viraj Paunikar was coordinating the oxygen factory audit in the Vidarbha region.
Apart from Butibori, FDA officials will also visit key players in oxygen production such as Aditya Air Products in Hingna, Aassi Cryogenic Private Limited in Butibori and Jagadamba Gas in Mauda.
It learns that civil surgeons and district health workers are conducting a similar oxygen factory audit in government places such as medical colleges, AIIMS and rural health centers and hospitals.